Abstract: Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component that includes an Glucocorticoid Derivative which, upon delivery to the posterior segment of a mammalian eye, does not significantly diffuse to the anterior segment of said eye. Methods of making and using the present materials are also described.
Abstract: Compounds of Formula 1 where X is S and the variables have the meaning defined in the specification are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors, and as such have no or only minimal cardiovascular and/or sedatory activity. These compounds of Formula 1 are useful as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2B adrenergic receptors. Compounds of Formula 1 where X is O also have the advantageous property that they have no or only minimal cardiovascular and/or sedatory activity and are useful for treating pain and other conditions with no or only minimal cardiovascular and/or sedatory activity.
Type:
Grant
Filed:
July 25, 2008
Date of Patent:
November 22, 2011
Assignee:
Allergan, Inc.
Inventors:
Ken Chow, Todd Heidelbaugh, Daniel Gill, Michael Garst, Larry A. Wheeler, Phong X. Nguyen, Dario G. Gomez
Abstract: Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof, are disclosed, wherein Y is A is —(CH2)6—, cis —CH2CH?CH—(CH2)3—, or —CH2C?C—(CH2)3—, wherein 1 or 2 carbon atoms may be substituted with S or O; or A is —(CH2)m—Ar—(CH2)o— wherein Ar is substituted or unsubstituted phenyl or monocyclic heteroaryl, the sum of m and o is from 1 to 4, and wherein one CH2 may be replaced with S or O; X is S or O; R is a hydrocarbyl or a hydroxyhydrocarbyl moiety having from 1 to 12 carbon atoms; D is independently a moiety comprising from 1 to 6 non-hydrogen atoms; and n is an integer from 0 to 4. Methods, compositions, and medicaments related thereto are also disclosed.
Type:
Grant
Filed:
January 13, 2009
Date of Patent:
November 22, 2011
Assignee:
Allergan, Inc.
Inventors:
David W. Old, Danny T. Dinh, Robert M. Burk
Abstract: Compounds of Formula 1 where X is S and the variables have the meaning defined in the specification are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors, and as such have no or only minimal cardiovascular and/or sedatory activity. These compounds of Formula 1 are useful as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2B adrenergic receptors. Compounds of Formula 1 where X is O also have the advantageous property that they have no or only minimal cardiovascular and/or sedatory activity and are useful for treating pain and other conditions with no or only minimal cardiovascular and/or sedatory activity.
Type:
Grant
Filed:
October 17, 2007
Date of Patent:
November 22, 2011
Assignee:
Allergan, Inc.
Inventors:
Ken Chow, Todd M. Heidelbaugh, Daniel W. Gil, Michael E. Garst, Larry A. Wheeler
Abstract: This invention provides compounds as shown below, in which either all of Z1-6 are carbon or one of Z1-6 is nitrogen and the rest are carbon, and in which other substituents are defined herein, which are sphingosine-1-phosphate antagonists.
Type:
Grant
Filed:
August 12, 2009
Date of Patent:
November 1, 2011
Assignee:
Allergan, Inc.
Inventors:
Phong X. Nguyen, Todd M. Heidelbaugh, Ken Chow
Abstract: A compound having a substituted five or six-membered carbocycle or heterocycle directly bonded to a substituted aryl or heteroaryl ring, wherein said compound has an EC50 value of 20 nM or less at the prostaglandin EP2 receptor according to the cAMP assay. Methods, compositions, and medicaments related thereto are also disclosed.
Type:
Grant
Filed:
August 20, 2010
Date of Patent:
October 25, 2011
Assignee:
Allergan, Inc.
Inventors:
Yariv Donde, Robert M. Burk, David W. Old
Abstract: Disclosed herein is a compound having a structure or a pharmaceutically acceptable salt or a prodrug thereof; wherein Y, A, X, R and D are as described. Methods, compositions, and medicaments related thereto are also disclosed.
Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
Abstract: Compounds of the formula where the variables have the meaning defined in the specification have analgesic and/or immunostimulant effect in mammals.
Type:
Grant
Filed:
January 25, 2006
Date of Patent:
September 6, 2011
Assignee:
Allergan, Inc.
Inventors:
Bertrand Leblond, Eric Beausoleil, Thierry Taverne, John E. Donello
Abstract: Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.
Type:
Grant
Filed:
May 28, 2004
Date of Patent:
August 30, 2011
Assignee:
Allergan, Inc.
Inventors:
Christopher A. Muller, Janet K. Cheetham, Teresa H. Kuan, David F. Power
Abstract: Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the prostamide component may be encapsulated by the polymeric component. The present implants include oil-in-oil emulsified implants or microparticles. Methods of producing the present implants are also described. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.
Type:
Grant
Filed:
December 15, 2005
Date of Patent:
August 9, 2011
Assignee:
Allergan, Inc.
Inventors:
Patrick M. Hughes, Michele Boix, Christian Sarrazin, Marina Do
Abstract: A breast implant selector system including a breast width selector for selecting breast width input information, a breast tissue type selector for selecting breast tissue type input information in response to breast width input information selected with the breast width selector, and an implant size selector for selecting implant size input information in response to the breast tissue type input information selected with the breast tissue type selector. A result indicator provides a result characterizing at least one suggested breast implant as a function of the input breast width, breast tissue type, and implant size input information.
Type:
Grant
Filed:
February 18, 2010
Date of Patent:
July 19, 2011
Assignee:
Allergan, Inc.
Inventors:
William P. Adams, Jr., Bradley P. Bengtson, Steven A. Teitelbaum
Abstract: The present invention provides a method of preventing or reducing the severity of a stress-associated condition in a subject by systemically administering to the subject an effective amount of brimonidine or a pharmaceutically acceptable salt, ester, amide, stereoisomer or racemic mixture thereof. Stress-associated conditions that can be treated according to a method of the invention include, but are not limited to, dyspepsia, tachycardias other than tachycardia associated with myocardial ischemia, panic attack, non-inflammatory dermatological conditions, disorders of muscle contraction, sensory hypersensitivity associated with migraine, and behavioral disorders.
Type:
Grant
Filed:
May 2, 2008
Date of Patent:
July 12, 2011
Assignee:
Allergan, Inc.
Inventors:
Daniel W. Gil, Scott Whitcup, Mitchell F. Brin, John E. Donello
Abstract: The present invention provides a compound represented by the formula: wherein the variables R1, b, R6, Y, Z, X, R and a are defined in the specification. Said compound may be used in a method for treating diseases related to unregulated tyrosine kinase signal transduction, wherein said disease is selected from the group consisting of cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, and metabolic diseases.
Type:
Grant
Filed:
March 16, 2007
Date of Patent:
July 12, 2011
Assignee:
Allergan, Inc.
Inventors:
Sougato Boral, Xialing Guo, Shimiao Wang, Julie A. Wurster, Thomas C. Malone
Abstract: The present invention provides a method of treating glaucoma or ocular hypertension which comprises applying to the eye of a person in need thereof an amount sufficient to treat glaucoma or ocular hypertension of a compound of formula I wherein Y, Q, Z, R, R1 and R2 are as defined in the specification. The present invention further comprises pharmaceutical compositions, e.g. ophthalmic compositions, including said compound.
Type:
Grant
Filed:
April 24, 2007
Date of Patent:
June 28, 2011
Assignee:
Allergan, Inc.
Inventors:
June Chen, Simon N. Pettit, Hans G. Fliri
Abstract: Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component which includes an alpha 2 adrenergic receptor agonist that is cleared from the anterior segment of an individual's eye to which the material is administered. The alpha 2 adrenergic receptor agonist may have a vitreal half-life greater than about three hours. The present materials are effective in treating an ocular condition(s) that affect the anterior segment of an eye, or the anterior and posterior segment of the eye. The materials are suitable for intravitreal or periocular administration and can provide prolonged drug delivery and therapeutic benefits to patients to which the materials have been administered. The alpha 2 adrenergic receptor agonists can be provided in liquid-containing formulations and/or bioerodible and/or non-bioerodible polymeric implants and microparticles. Methods of making and using the present materials are also described.
Type:
Grant
Filed:
May 2, 2006
Date of Patent:
April 26, 2011
Assignee:
Allergan, Inc.
Inventors:
Patrick M. Hughes, James A. Burke, Joan-En Chang-Lin
Abstract: The present invention provides pharmaceutical compositions useful in a method for treating neuropathic pain, said method comprising administration of a pain-ameliorating effective amount of the compound according to formula I wherein R is an alk(en)yl group, R1 is an alkylen(yl) group, n is 0 or 1 and Ar is a carbocyclic aryl group.
Type:
Grant
Filed:
October 13, 2006
Date of Patent:
March 8, 2011
Assignee:
Allergan, Inc.
Inventors:
Vincenzo Di Marzo, Luciano De Petrocellis, Sabatino Malone, Vito De Novellis
Abstract: Methods and compositions for the treatment of conditions including stress-associated, chronic pain, and neurodegenerative conditions in a mammal using a composition comprising NB-DNJ or a compound structurally similar thereto.
Type:
Grant
Filed:
September 27, 2005
Date of Patent:
February 8, 2011
Assignee:
Allergan, Inc.
Inventors:
John E. Donello, Fabien J. Schweighoffer